Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

September 19, 2022

https://www.globenewswire.com/news-release/2022/09/19/2518203/33333/en/Coherus-to-Launch-CIMERLI-ranibizumab-eqrn-in-the-United-States-on-October-3-2022.html

– CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity –

Read more at globenewswire.com

Related news for (CHRS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.